Available at: http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt- adv-reactions.asp]. 11.4 E NZALUTAMIDE Please see FDA-approved packet insert for Enzalutamide for complete agent information. 11.4.1 Description and formulation Enzalutamide (XTANDI ©) is an androgen receptor inhibitor. The chemical name is 4-{3-[4- cyano-3-(trifluoromethyl)phenyl]-5,5- dimethyl -4-oxo-2-sulfanylideneimidazolidin-1-yl}-2- fluoro- N-methylbenzamide. Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients ar e caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gela tin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide. 11.4.2 Source Medivation and Astellas Inc.